ORPHENGESIC FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORPHENGESIC FORTE (ORPHENGESIC FORTE).
Opioid agonist; primarily mu-opioid receptor agonism, with additional kappa and delta receptor activity, leading to altered pain perception and analgesic response.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2D6; major metabolites: morphine-3-glucuronide (M3G), morphine-6-glucuronide (M6G). |
| Excretion | Renal: 87% (55% unchanged, 32% as glucuronide conjugate); Biliary/Fecal: <5% as metabolites. |
| Half-life | 2-4 hours; prolonged to 10-20 hours in hepatic impairment. |
| Protein binding | 90-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.5-3.0 L/kg; extensive tissue distribution, notably to brain and skeletal muscle. |
| Bioavailability | Oral: 85-90%; Rectal: 70-80% (first-pass metabolism). |
| Onset of Action | Oral: 15-30 minutes; Rectal: 30-45 minutes; IM: 10-15 minutes. |
| Duration of Action | Oral/IM/Rectal: 3-5 hours; extended-release formulations: 8-12 hours. |
1-2 tablets (325-650 mg acetaminophen/30-60 mg codeine) orally every 4-6 hours as needed; maximum 8 tablets per day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: administer every 6 hours; GFR 10-29 mL/min: administer every 8 hours; GFR <10 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated. |
| Pediatric use | Weight-based dosing: Acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day. Not for children <12 years due to codeine safety concerns. |
| Geriatric use | Start at low end of dosing (e.g., 1 tablet every 6 hours) due to increased sensitivity and risk of respiratory depression. Maximum 4 tablets per day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORPHENGESIC FORTE (ORPHENGESIC FORTE).
| Breastfeeding | Orphengesic Forte components are excreted into breast milk. Aspirin: M/P ratio ~0.01-0.1; risk of Reye syndrome in infant; avoid high doses. Orphenadrine: M/P ratio unknown; may cause anticholinergic effects (drowsiness, irritability). Caffeine: M/P ratio ~0.5-0.8; can cause infant irritability and sleep disturbances. Recommend avoiding due to potential adverse effects. |
| Teratogenic Risk | Orphengesic Forte (orphenadrine citrate, aspirin, and caffeine) carries significant teratogenic risk due to aspirin. First trimester: Aspirin is associated with neural tube defects and cardiovascular malformations (odds ratio ~2-3). Second trimester: Possible increased risk of gastroschisis. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, and fetal intracranial hemorrhage. Orphenadrine: Limited human data; animal studies show no consistent teratogenicity. Caffeine: High doses (>300 mg/day) may increase miscarriage risk. Overall: Contraindicated in pregnancy, especially third trimester. |
■ FDA Black Box Warning
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants.
| Serious Effects |
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction including paralytic ileus; hypersensitivity to morphine or any component.
| Precautions | Respiratory depression; hypotension; seizure risk; serotonin syndrome; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; impaired mental/physical abilities. |
Loading safety data…
| Fetal Monitoring | Monitor maternal: Liver function tests (aspirin hepatotoxicity), renal function, bleeding time (aspirin antiplatelet effect). Fetal: Ultrasound for ductus arteriosus and amniotic fluid index if exposed in third trimester. Neonatal: Observe for bruising, bleeding, and signs of premature ductus closure. No specific monitoring for orphenadrine or caffeine. |
| Fertility Effects | Aspirin: May inhibit ovulation via prostaglandin synthesis blockade; reversible. Orphenadrine: No known direct effect on fertility. Caffeine: High intake (>300 mg/day) associated with delayed conception and increased risk of infertility. Overall: Potential reversible impairment of fertility with high-dose caffeine and aspirin. |